Mixed protocols: Multiple ratios of FSH and LH bioactivity using highly purified, human-derived FSH (BRAVELLE) and highly purified hMG (MENOPUR) are unaltered by mixing together in the same syringe

Table 3 Seminal vesicle weights in rats injected with a low, middle and a high dose of the Reference Standard, Menopur^®, or a mixture of Bravelle^® and Menopur^® reconstituted in 0.9% saline and mixed in the same syringe.

Hormone (FSH:LH)^a	Total no. rats	Seminal Vesicle weights (mean ± SEM)^b*
		Low^c dose	Middle^d dose	High^e dose
Reference Standard	48	35.82 ± 1.64	68.88 ± 2.40	96.39 ± 2.95
Menopur^® (75:75)	48	36.49 ± 1.54	72.55 ± 1.61	95.69 ± 2.87
Bravelle^®+ Menopur^®
(150:75)	48	36.47 ± 1.23	73.94 ± 2.42	96.62 ± 1.70
(300:75)	48	37.80 ± 1.25	74.57 ± 1.57	94.49 ± 2.09
(300:225)	48	36.28 ± 1.50	74.78 ± 1.78	95.73 ± 2.01

* The magnitude of this increase was similar across treatment groups (treatment × dose P = 0.74)
^a Ratio of FSH:LH bioactivity expressed in IUs
^b Combined seminal vesicle weights from the 2 replicates (replicate × treatment × dose)
^c Low dose = 7 IU LH/0.8 mL
^d Middle dose = 14 IU LH/0.8 mL
^e High dose = 28 IU LH/0.8 mL

ISSN: 1477-7827